Ophthalmology and therapy · 2025
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ohnaka Masayuki, Sakurada Yoichi, Hayashi Atsushi, Kadonosono Kazuaki, Ohno Hitoshi, Mori Ryusaburo, Matsumoto Hidetaka, Nagamori Ippei, Murata Yuki, Maio-Twofoot Tina, Karcher Helene, Takahashi Hidenori
Аннотация
INTRODUCTION: The aim of this study was to evaluate the real-world outcomes of brolucizumab use in Japanese patients with neovascular age-related macular degeneration (nAMD).
METHODS: PHEASANT was a retrospective, multicenter, single-arm cohort study. The study included 438 patients, of whom 123 were treatment-naïve and 315 were pre-treated. The primary outcome was retinal fluid (subretinal fluid [SRF] and intraretinal fluid [IRF]) resolution at month 12, with change in visual and retinal anatomy parameters and safety assessed as key secondary outcomes.
RESULTS: At baseline in the treatment-naïve cohort, 10.1% (n = 7/69) of patients were free of retinal fluid, increasing to 62.3% (n = 43/69) at month 12. In the pre-treated cohort, 14.9% (n = 30/201) of patients were free of retinal fluid at baseline, increasing to 43.8% (n = 88/201) at month 12. The median (interquartile range [IQR]) injection interval for pre-treated patients at month 12 was extended by 21 (7.0-35.0) days. The overall intraocular inflammation rate (including the rate of retinal vasculitis/retinal occlusive vasculitis of 0.46% [2/438]) was 8.4% (n = 37/438).
CONCLUSION: In a real-world clinical setting, brolucizumab was effective at drying the retina in treatment-naïve and pre-treated Japanese nAMD patients and therefore has the potential to reduce the treatment burden by prolonging injection intervals. Safety outcomes support the overall favorable benefit/risk profile of brolucizumab.
GOV IDENTIFIER: NCT06699914.
METHODS: PHEASANT was a retrospective, multicenter, single-arm cohort study. The study included 438 patients, of whom 123 were treatment-naïve and 315 were pre-treated. The primary outcome was retinal fluid (subretinal fluid [SRF] and intraretinal fluid [IRF]) resolution at month 12, with change in visual and retinal anatomy parameters and safety assessed as key secondary outcomes.
RESULTS: At baseline in the treatment-naïve cohort, 10.1% (n = 7/69) of patients were free of retinal fluid, increasing to 62.3% (n = 43/69) at month 12. In the pre-treated cohort, 14.9% (n = 30/201) of patients were free of retinal fluid at baseline, increasing to 43.8% (n = 88/201) at month 12. The median (interquartile range [IQR]) injection interval for pre-treated patients at month 12 was extended by 21 (7.0-35.0) days. The overall intraocular inflammation rate (including the rate of retinal vasculitis/retinal occlusive vasculitis of 0.46% [2/438]) was 8.4% (n = 37/438).
CONCLUSION: In a real-world clinical setting, brolucizumab was effective at drying the retina in treatment-naïve and pre-treated Japanese nAMD patients and therefore has the potential to reduce the treatment burden by prolonging injection intervals. Safety outcomes support the overall favorable benefit/risk profile of brolucizumab.
GOV IDENTIFIER: NCT06699914.